Spots Global Cancer Trial Database for bendamustine
Every month we try and update this database with for bendamustine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | NCT00947388 | Recurrent Small... Refractory Chro... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Bendamustine Hy... Alemtuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma | NCT04002297 | Mantle Cell Lym... | zanubrutinib bendamustine rituximab | 60 Years - | BeiGene | |
| Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | NCT00963534 | Mantle Cell Lym... | lenalidomide, b... lenalidomide, b... | 65 Years - | Lund University Hospital | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma | NCT01691807 | Cancer | ofatumumab bendamustine | 18 Years - | Novartis | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | NCT01315873 | Multiple Myelom... | Bendamustine Bortezomib | 18 Years - | NYU Langone Health | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | NCT03609593 | Chronic Lymphoc... | Bendamustine Venetoclax Rituximab | 18 Years - 99 Years | Columbia University | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01594229 | Non-Hodgkin's L... | ABT-199 Rituximab Bendamustine | 18 Years - 99 Years | AbbVie | |
| Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | NCT01029730 | Lymphoma | Bendamustine Bortezomib Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | NCT01332617 | Myeloma | Simvastatin,Zol... | 18 Years - | University of Louisville | |
| Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia | NCT00274989 | Chronic Lymphoc... | Bendamustine Rituximab | 18 Years - | German CLL Study Group | |
| A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). | NCT04236141 | Diffuse, Large ... | Polatuzumab Ved... Bendamustine Rituximab Placebo | 18 Years - | Hoffmann-La Roche | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | NCT01974440 | Lymphoma | Bendamustine Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone PCI-32765 (Ibru... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | NCT01317901 | B-cell Small Ly... | TRU-016 Bendamustine Rituximab | 18 Years - 99 Years | Aptevo Therapeutics | |
| Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | NCT00758693 | Chronic Lymphoc... | Bendamustine Rituximab | 65 Years - | University of Kentucky | |
| Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT01168804 | Multiple Myelom... | bendamustine pl... | 18 Years - | Austrian Forum Against Cancer | |
| Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | NCT01458366 | Non-Hodgkin's L... | Bendamustine Ofatumumab Carboplatin Etoposide CT Scan PET Scan Stem Cell Trans... | 18 Years - | Thomas Jefferson University | |
| Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | NCT01042704 | Myeloma | Bendamustine Lenalidomide Dexamethasone Aspirin Prophylaxis Antibiotic Biweekly Follow... Cyclical Follow... Restaging Post-Treatment ... | 18 Years - | University of Pittsburgh | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years | NCT03492775 | Indolent Non-ho... | Obinutuzumab Bendamustine | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | NCT01059786 | Hairy Cell Leuk... | Pentostatin Rituximab Bendamustine Acetaminophen Diphenhydramine Epinephrine Antihistamines Corticosteroids Bronchodilators Intravenous (IV... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | NCT05848765 | Relapsed Follic... Refractory Foll... | Epcoritamab Lenalidomide Rituximab Obinutuzumab Bendamustine Vincristine Doxorubicin Cyclophosphamid... Prednisone Investigation a... Investigation a... | 18 Years - | University of Birmingham | |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | NCT01352312 | Chronic Lymphoc... B-Cell Non-Hodg... | Bendamustine Pentostatin Ofatumumab | 18 Years - | Thomas Jefferson University | |
| Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | NCT00834678 | Breast Cancer | bendamustine erlotinib Maintenance erl... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma | NCT02423837 | Follicular Lymp... | Rituximab, bend... | 18 Years - 75 Years | National Research Center for Hematology, Russia | |
| A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma | NCT01929265 | Indolent Non-fo... Non-Hodgkin's L... | Bendamustine | 18 Years - 75 Years | Fondazione Italiana Linfomi - ETS | |
| Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | NCT01423032 | Chronic Lymphoc... | bendamustine Fludarabine | 18 Years - | WiSP Wissenschaftlicher Service Pharma GmbH | |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | NCT01078142 | Follicular Lymp... Mantle Cell Lym... | Temsirolimus, R... | 18 Years - | Johannes Gutenberg University Mainz | |
| Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma | NCT05006469 | Bendamustine Multiple Myelom... | Bendamustine | 18 Years - | Shengjing Hospital | |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | NCT04245722 | Lymphoma, B-Cel... Chronic Lymphoc... | FT596 Cyclophosphamid... Fludarabine Rituximab Obinutuzumab Bendamustine | 18 Years - | Fate Therapeutics | |
| Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL | NCT00385125 | Lymphoma, High-... | Bendamustine Rituximab | 18 Years - | University of Magdeburg | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | NCT02315157 | Multiple Myelom... Plasma Cell Leu... | Bendamustine | 18 Years - 80 Years | Thomas Jefferson University | |
| A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT01671904 | Chronic Lymphoc... | Bendamustine Obinutuzumab Rituximab Venetoclax | 18 Years - | Genentech, Inc. | |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | NCT01974440 | Lymphoma | Bendamustine Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone PCI-32765 (Ibru... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | NCT01905943 | Chronic Lymphoc... | Bendamustine Chlorambucil Cyclophosphamid... Fludarabine Obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma | NCT01686321 | Aggressive Lymp... | Bendamustine an... | 60 Years - | University of Göttingen | |
| A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | NCT02954406 | Lymphoma, Non-H... | TAK-659 Bendamustine Rituximab Gemcitabine Lenalidomide Ibrutinib | 18 Years - | Takeda | |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | NCT05934097 | Diffuse Large B... Transformed Ind... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | FT596 Cyclophosphamid... Doxorubicin Vincristine Prednisone Rituximab Bendamustine | 18 Years - | Fate Therapeutics | |
| Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer | NCT01891227 | Breast Cancer | Capecitabine Bendamustine | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Study of Mantle Cell Lymphoma Treatment by RiBVD | NCT01457144 | Mantle Cell Lym... | RiBVD | 65 Years - 85 Years | French Innovative Leukemia Organisation | |
| A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia | NCT02071225 | Chronic Lymphoc... | bendamustine obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT02187133 | Lymphoma, Non-H... Lymphoma | Carfilzomib Bendamustine Rituximab | 18 Years - | University of California, San Francisco | |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | NCT04515238 | Chronic Lymphoi... | Bendamustine Obinutuzumab Zanubrutinib Venetoclax | 18 Years - | German CLL Study Group | |
| A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT02005471 | Chronic Lymphoc... | Bendamustine Venetoclax Rituximab | 18 Years - | Hoffmann-La Roche | |
| Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma | NCT00740415 | Lymphoma | rituximab bortezomib dexamethasone Bendamustine | 65 Years - 80 Years | French Innovative Leukemia Organisation | |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02623920 | Diffuse Large B... Mediastinal Lar... Grey Zone Lymph... High Grade B Ce... Follicular Lymp... Marginal Zone L... Small Lymphocyt... | Brentuximab Bendamustine Rituximab | 18 Years - | University of Arizona | |
| Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia | NCT02110394 | Chronic Lymphoc... | bendamustine rituximab | 18 Years - | Astellas Pharma Inc | |
| A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT02763319 | Diffuse Large B... | Rituximab (RTX) Tafasitamab Bendamustine (B... | 18 Years - | MorphoSys AG | |
| Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors | NCT00837928 | Metastatic Canc... Unspecified Adu... | bendamustine laboratory biom... Surgical Resect... Stereotactic bo... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age | NCT03834688 | Mantle Cell Lym... | Venetoclax Bendamustine Rituximab | 60 Years - | PrECOG, LLC. | |
| Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors | NCT00837928 | Metastatic Canc... Unspecified Adu... | bendamustine laboratory biom... Surgical Resect... Stereotactic bo... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | NCT01376401 | Multiple Myelom... | Bendamustine Velcade Prednisone | - | PETHEMA Foundation | |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | NCT06415708 | B Cell Lymphoma | Obinutuzumab Co... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | NCT02072967 | Lymphoma, Non-H... | Ribomustin rituximab | 18 Years - | Astellas Pharma Inc | |
| Observational Study in CLL Patients Receiving BR | NCT02381899 | Chronic Lymphoc... | Bendamustine an... | 18 Years - | Czech CLL Study Group | |
| Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL | NCT01612988 | B-cell Chronic ... | BOMP | 18 Years - 80 Years | French Innovative Leukemia Organisation | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia | NCT01088984 | Leukemia | Bendamustine | 1 Year - 20 Years | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT01168804 | Multiple Myelom... | bendamustine pl... | 18 Years - | Austrian Forum Against Cancer | |
| Bendamustine and Melphalan in Myeloma | NCT03187223 | Multiple Myelom... | Melphalan Bendamustine | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | NCT03406156 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab Bendamustine Venetoclax | 18 Years - 99 Years | AbbVie | |
| Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | NCT03872180 | CCND1 Positive Mantle Cell Lym... t(11;14) Positi... | Bendamustine Obinutuzumab Venetoclax | 18 Years - | Emory University | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | NCT01661881 | Mantle Cell Lym... | Rituximab Bendamustine Cytarabine | 18 Years - 69 Years | Dana-Farber Cancer Institute | |
| Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | NCT06043713 | Metastatic Colo... Metastatic Lung... Metastatic Panc... Stage IV Colore... Stage IV Lung C... Stage IV Pancre... | Bendamustine Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Magnetic Resona... Multigated Acqu... Positron Emissi... T-cell Receptor... | 18 Years - | Fred Hutchinson Cancer Center | |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma | NCT01661881 | Mantle Cell Lym... | Rituximab Bendamustine Cytarabine | 18 Years - 69 Years | Dana-Farber Cancer Institute | |
| Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT00831597 | Diffuse Large B... | bendamustine rituximab | 18 Years - | Pharmatech | |
| FT819 in Subjects With B-cell Malignancies | NCT04629729 | Lymphoma, B-Cel... Chronic Lymphoc... Precursor B-Cel... | FT819 Cyclophosphamid... Fludarabine IL-2 Bendamustine | 18 Years - | Fate Therapeutics | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | NCT04245722 | Lymphoma, B-Cel... Chronic Lymphoc... | FT596 Cyclophosphamid... Fludarabine Rituximab Obinutuzumab Bendamustine | 18 Years - | Fate Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
